Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03725059
Brief Title: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

First Submitted : October 29, 2018
First Submitted that Met QC Criteria : October 29, 2018
First Posted : October 30, 2018

Last Update Submitted that Met QC Criteria : October 8, 2021
Last Update Posted : October 11, 2021